Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 3 1

Status

Unknown 5Recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 4606Pancreatic Neoplasms 2845Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Colonic Neoplasms 1791Rectal Neoplasms 1720Esophageal Neoplasms 1376Liver Neoplasms 921Neoplasms 915Breast Neoplasms 839Neoplasm Metastasis 765Carcinoma, Non-Small-Cell Lung 707Cholangiocarcinoma 587Lung Neoplasms 557Ovarian Neoplasms 535Esophageal Squamous Cell Carcinoma 514Gastrointestinal Neoplasms 495Melanoma 381Prostatic Neoplasms 373Biliary Tract Neoplasms 373Head and Neck Neoplasms 303Uterine Cervical Neoplasms 288Carcinoma, Renal Cell 284Adenocarcinoma Of Esophagus 273Squamous Cell Carcinoma of Head and Neck 264Sarcoma 264Gastrointestinal Stromal Tumors 252Endometrial Neoplasms 235Urinary Bladder Neoplasms 226Gallbladder Neoplasms 225

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Borderline Resectable Pancreatic Cancer × Gastrointestinal × Clear all
NCT06387810 2024-07-10

undetermined

Peking Union Medical College Hospital

Phase 2 Recruiting
45 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04855331 2023-05-09

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Fudan University

Phase NA Unknown
120 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Fudan University

Phase 3 Unknown
300 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡